Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges
Source: SeekingAlpha
2025-05-08 19:09:28 ET
More on Pacific Biosciences of California
- Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
- Pacific Biosciences of California, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
- Pacific Biosciences of California Q1 2025 Earnings Preview
- Pacific Biosciences of California jumps 22% after prelim Q1 results, guides FY
Read the full article on Seeking Alpha
For further details see:
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges
Pacific Biosciences of California Inc.
NASDAQ: PACB
PACB Trading
3.38% G/L:
$1.375 Last:
2,195,188 Volume:
$1.36 Open:
PACB Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 24, 2026 09:05:00 am
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
February 18, 2026 04:05:00 pm
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
PACB Stock Data
$549,471,524
294,359,745
0.64%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
